Literature DB >> 31737336

Invited correspondence on: "Aspirin for patients undergoing major lung resections: hazardous or harmless?"

Antje Messerschmidt1,2, Davor Stamenovic1.   

Abstract

Entities:  

Year:  2019        PMID： 31737336      PMCID： PMC6837977          DOI： 10.21037/jtd.2019.09.70

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Safety of perioperative low dose aspirin therapy in major lung resection.

Authors:  Woo Sik Yu; Chang Young Lee
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

2.  Safety of thoracoscopic surgery for lung cancer without interruption of anti-platelet agents.

Authors:  Woo Sik Yu; Hee Suk Jung; Jin Gu Lee; Dae Joon Kim; Kyung Young Chung; Chang Young Lee
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

3.  Non-cardiac surgery in patients with coronary stents: the RECO study.

Authors:  Pierre Albaladejo; Emmanuel Marret; Charles-Marc Samama; Jean-Philippe Collet; Kou Abhay; Olivier Loutrel; Hélène Charbonneau; Samir Jaber; Sophie Thoret; Jean-Luc Bosson; Vincent Piriou
Journal:  Heart       Date:  2011-07-26       Impact factor: 5.994

Review 4.  Perioperative aspirin management after POISE-2: some answers, but questions remain.

Authors:  Neal Stuart Gerstein; Michael Christopher Carey; Joaquin E Cigarroa; Peter M Schulman
Journal:  Anesth Analg       Date:  2015-03       Impact factor: 5.108

Review 5.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

Authors:  Enrico Flossmann; Peter M Rothwell
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

6.  Aspirin for patients undergoing major lung resections: hazardous or harmless?†.

Authors:  Davor Stamenovic; Thomas Schneider; Antje Messerschmidt
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-04-01

7.  Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.

Authors:  Farhat V N Din; Asta Valanciute; Vanessa P Houde; Daria Zibrova; Kevin A Green; Kei Sakamoto; Dario R Alessi; Malcolm G Dunlop
Journal:  Gastroenterology       Date:  2012-03-06       Impact factor: 22.682

8.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Authors:  Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-12-06       Impact factor: 79.321

9.  A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark.

Authors:  E T Chang; T Frøslev; H T Sørensen; L Pedersen
Journal:  Br J Cancer       Date:  2011-10-25       Impact factor: 7.640

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.